The induced pluripotent stem cell (iPS cell) derived co culture sits inside the IVF process to support egg maturation in the lab; Shionogi, a major Japanese pharmaceutical company, has joined as a strategic investor alongside a Japanese government deep tech grant and a TIME100…
Dioseve's founders keep coming back to the same moment: the roughly ten days of hormone injections, monitoring visits, and waiting rooms that frame every IVF cycle. The Tokyo biotech is not trying to replace that process. It is trying to soften it by adding a layer of lab-grown support cells, derived from induced pluripotent stem cells (iPS cells), alongside a patient's eggs during the lab maturation step before fertilization.
On June 16, 2026, Dioseve announced it had secured JPY 1.45 billion to keep testing that approach. The headline number is a composite. Roughly JPY 1 billion came from an extended Series A round of dilutive equity, which the company said brings its cumulative equity raised to JPY 2.5 billion. The remaining portion is non-dilutive support from the Japan New Energy and Industrial Technology Development Organization (NEDO), a government-backed funder that selected Dioseve for the eighth cohort of its Deep Tech Startup Support Program (DTSU), which the release describes as a Japanese government-backed initiative for high-risk, high-impact deep tech. When combined, the company's total funding to date reaches JPY 2.9 billion.
That capital structure is the part of the story the wire lede buries. A biotech raising dilutive capital and capturing public grant support in the same announcement signals two things at once: investors willing to underwrite a private round at a disclosed valuation, and a government program that has independently judged the underlying science risky enough to subsidize. The DTSU in particular is structured for work that private capital alone would not support, which makes the selection a form of third-party validation that investors and regulators both read.
The science is also narrower than the iPS-cell label suggests. Dioseve's lead candidate, ReproNest (also referred to as DIOS-101 in earlier company materials), is not a cell therapy injected into a patient. It is a co-culture: iPS-derived ovarian support cells grown in the same dish as a patient's eggs during the in vitro maturation window, where the company's hypothesis is that the helper cells improve the proportion of eggs that mature to a fertilization-ready state. Preclinical data to date suggest that ReproNest may improve oocyte maturation under experimental conditions compared with standard IVM culture systems, the company said. The product sits inside the existing IVF workflow rather than displacing it, and the company frames the goal as reducing cycle-to-cycle physical and emotional load on patients, not changing who qualifies for treatment.
The investor list tells a second story. Archetype Ventures led the equity round, with continuing participation from DG Daiwa Ventures and Mirai Door (the Asuka Innovation Fund). New investors joining the round include D4V, Pangaea Ventures, and Shionogi & Co. The Shionogi name is the one worth pausing on. Shionogi is a major Japanese pharmaceutical company, and Dioseve described that position — in a reproductive biotech rather than a passive financial one — as a signal that Japanese large pharma may be beginning to treat reproductive medicine as a portfolio priority, not a curiosity.
A third thread sits in the advisor bench. Dioseve said it had added Professor Katsuhiko Hayashi of Osaka University's Graduate School of Medicine to its advisory ranks. Hayashi, a globally recognized pioneer in reproductive biology and a 2024 TIME100 honoree, has published numerous landmark findings in germ cell research using iPS cells. His involvement, the company said, is expected to deepen Dioseve's scientific foundation and accelerate progress toward new treatment options in assisted reproductive medicine.
The open questions are concrete. ReproNest is pre-clinical by any standard read of the release, and the company has not yet published peer-reviewed data on the co-culture's effect on maturation rates in human eggs. The JPY 1.45 billion buys time to answer those questions in the lab and, eventually, in a regulatory dialogue. NEDO's selection de-risks part of the bill. The Shionogi check de-risks a different question: whether a major Japanese pharma will eventually be the commercial partner that takes a co-culture product from a research lab to a fertility clinic. The watch items for the rest of 2026 are peer-reviewed maturation data, the regulatory pathway for ReproNest, and Shionogi's first public framing of what it expects from the position.